ACS Medicinal Chemistry Letters · 2011 · 65 citations · 14 references
PharmacyMedicinal ChemistryPharmacologyBioavailabilityDrug DiscoveryLead OptimizationDrug DispositionHit-to-lead OptimizationLead Compound DesignOral Bioavailability EnhancementPharmacokinetic OptimizationPotency OptimizationCompound Potency OptimizationDrug Candidate OptimizationOral Bioavailability OptimizationOral Drug BioavailabilityRelative Oral Bioavailability
New spiroindolinone antagonists of CRTH2 are described. Following identification of insufficient stability in human plasma as an important liability of the lead compounds, replacement of the spirosuccinimide core with a spirohydantoin or spiropyrrolidinone structure has yielded a compound that is fully stable in human plasma and with good potency in a human whole blood assay (IC50 = 69 nM) but shows a much lower oral bioavailability (6-9% in rodents) than the earlier compounds. Successive optimization aimed at restoring an acceptable oral bioavailability has yielded compound (S)-17a, which exhibits both stability in human plasma and a good oral bioavailability in rat (37%) and mouse (39%). This compound is also active in a mouse model of ovalbumin-induced lung inflammation following oral dosing at 30 mg/kg.
14
Hiroyuki Hirai, Kazuya Tanaka, Osamu Yoshie et al. · The Journal of Experimental Medicine · 2001 · 1.1K citations · Full text
Hamida Hammad, Hendrik Jan de Heer, Thomas Soullié et al. · The Journal of Immunology · 2003 · 191 citations · Full text